J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
The Journal of Clinical Pharmacology, 1974; 14:280-289
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer, J. S.
Right arrow Articles by Rivera, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, J. S.
Right arrow Articles by Rivera, V. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Orally Administered Betahistine and Regional Cerebral Blood Flow in Cerebrovascular Disease

John Stirling Meyer M.D., C.M., M.Sc.1, Ninan T. Mathew M.D., F.R.C.P. (Can.)1, Alexander Hartmann M.D.1, and Victor M. Rivera M.D.1

1 Department of Neurology, Baylor College of Medicine; Baylor-Methodist Center for Cerebrovascular Research, Houston, Tex.

In ten patients with chronic ischemic cerebrovascular disease, regional cerebral blood flow measurements were performed using clearance of xenon 133 and the gamma camera before and seven to eight days after initiation of oral betahistine therapy. Regional cerebral blood flow (rCBF) showed statistically significant increases after medication. Of the 115 regions of the cerebral hemispheres measured, 63 per cent showed significant increases in rCBF while only 5 per cent showed significant reduction, taking into account the reproducibility of the method of measurement. It is concluded that orally administered betahistine hydrochloride is a potent and effective drug for increasing cerebral blood flow in patients with cerebrovascular disease.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1974 by the American College of Clinical Pharmacology